Integrated Pulmonary Index and Opioid Based Patient Controlled Analgesia
Brain Tumors
About this trial
This is an interventional treatment trial for Brain Tumors focused on measuring Integrated pulmonary index, opioid side effects
Eligibility Criteria
Inclusion Criteria: , brain tumors, elective supratentorial craniotomies,
- Conscious patients
- Elective supratentorial craniotomies
- ASA I-III
Exclusion Criteria:
- Unconscious postoperatively
- Chronic pain
- Opioid, dexketoprofen or paracetamol allergy
- Delirium
- Renal insufficiency
- Alcohol, opioid dependency
- Transsphenoidal pituitary surgery
Sites / Locations
- Istanbul University Cerrahpasa Medical School
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Morphine PCA 1 mg
Morphine PCA 0,5 mg
Placebo
The patient controlled analgesia device give 1mg morphine for each demand of the patient.
The patient controlled analgesia device give 0,5 mg morphine for each demand of the patient.
The patient controlled analgesia device give 2 mL serum physiologic for each demand of the patient.The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours. If the VAS skore more than 4 the Group 3 patients will take 1 g paracetamol every 6 hours.